Stock Financial Ratios, Dividends, Split History

FPI / Farmland Partners Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)200.50
Enterprise Value ($M)720.82
Book Value ($M)357.35
Book Value / Share10.87
Price / Book0.57
NCAV / Sharen/a
Price / NCAVn/a
Share Statistics
Weighted Average Number Of Diluted Shares Outstanding 31,210,000
Weighted Average Number Of Shares Outstanding Basic 31,210,000
Common Shares Outstanding 33,334,849
Pro Forma Weighted Average Shares Outstanding Diluted 32,340,000
Common Stock Shares Outstanding Fully Diluted 38,000,000
Common Stock Shares Outstanding 33,334,849
Weighted Average Basic Shares Outstanding Pro Forma 32,340,000
Temporary Equity Shares Outstanding 6,037,500
Scoring Models
Piotroski F-Score3.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.01
Return on Assets (ROA)0.01
Return on Equity (ROE)0.04
Balance Sheet (mrq) ($M)
Quick Ration/a
Current Ration/a
Income Statement (mra) ($M)
Real Estate Revenue Net46,219,000.00
Crop Revenue799,000.00
Operating Income22.53
Net Income9.16
Earnings Per Share Diluted0.03
Earnings Per Share Basic0.03
Cash Flow Statement (mra) ($M)
Cash From Operations0.93
Cash from Investing-234.11
Cash from Financing-234.11
Identifiers and Descriptors
Central Index Key (CIK)1591670

Split History

Stock splits are used by Farmland Partners Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

Farmland Partners: The Smell Test

18h seekingalpha
While I admire the effort to track down the facts, the theory that FPI was inflating revenues did not smell right to me. This bear became a bull.

Top Analyst Upgrades and Downgrades: Avon, Broadcom, CDW, CSX, Goldman Sachs, Starbucks, Twitter, Under Armour, Windstream and More

2018-07-18 247wallst
Stocks were looking for direction on Wednesday with a fairly light day on economic data. Investors have had less faith and have seen lower rewards from buying the dips than in prior years. Many of those same investors have also been concerned about how they want their investments positioned ahead of the midterm elections, into international trade concerns and also for the longer term, into 2019 and beyond. (25-1)

Heard On The REITs - Ho Hum Week As We Await Earnings Season

2018-07-15 seekingalpha
The MSCI US REIT Index has underperformed the S&P 500 for two weeks in a row despite remaining relatively flat. (2-0)

Summer Screens And Shorts Coming Out

2018-07-13 seekingalpha
On the long side, there's a mix of screener ideas, what to do after the market sells the news, and one case of trying to get ahead of news. (17-0)

Farmland Partners: Why We Bought On The Crash

2018-07-13 seekingalpha
As most of you already know, Farmland Partners (FPI) dropped almost 40% on 7/11/18 related to a short article from someone with the pseudonym Rota Fortunae in which the author insinuated various financial shenanigans. Some of the issues raised had been the topic of discussion previously while others were newly introduced. This was not the first bearish article on FPI and it will likely not be the last.

CUSIP: 31154R109